Younger patients, despite receiving similar treatments, exhibited poorer survival outcomes, likely due to higher tumor aggression (as evidenced by increased Ki67 and higher histological grade) and more advanced disease at diagnosis. This evidence concerns the gene MKI67 and neoplasm.